New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Eva K. Havrdová: Nové trendy v léčbě RS | RS kompas
Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data - touchNEUROLOGY
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges - Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová, Ludwig Kappos, Xavier Montalban, Carlo Pozzilli,
Prezentace aplikace PowerPoint
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield proces
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
Untitled
Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations_ Integrated Analysis of the Delayed
Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | PLOS ONE
Clinical Advances in MS: Changing the Future for Patients
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Solen: On-line kurz pro praktické neurology 2/2022 - Léčba pacienta s RS v průběhu dekád života
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study | PLOS ONE
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
MUDr. Havrdová: Nová kritéria diagnostiky RS | RS kompas
